Published in Curr Med Res Opin on October 10, 2014
Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. J Am Med Inform Assoc (2016) 1.00
Pulse pressure as an independent predictor of stroke: a systematic review and a meta-analysis. Clin Res Cardiol (2016) 0.75
Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer (2013) 2.10
Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost. J Med Econ (2014) 2.00
Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol (2006) 1.89
The WRP component of the WAVE-1 complex attenuates Rac-mediated signalling. Nat Cell Biol (2002) 1.77
Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med (2010) 1.75
Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia (2007) 1.70
Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension (2012) 1.65
Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization. Neurology (2012) 1.62
The Cdc42 effector IRSp53 generates filopodia by coupling membrane protrusion with actin dynamics. J Biol Chem (2008) 1.60
The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD (2010) 1.59
Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Med Oncol (2011) 1.55
Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia. Cancer (2009) 1.54
Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion (2009) 1.53
Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications. Pain Med (2010) 1.51
Sprouty2 inhibits the Ras/MAP kinase pathway by inhibiting the activation of Raf. J Biol Chem (2001) 1.46
Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause (2015) 1.45
The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease. Curr Med Res Opin (2006) 1.41
The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective. Dis Manag (2008) 1.38
Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin (2014) 1.36
Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study. Epilepsia (2008) 1.32
Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm (2009) 1.25
Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer (2006) 1.20
Economic impact of dementia in developing countries: an evaluation of costs of Alzheimer-type dementia in Argentina. Int Psychogeriatr (2006) 1.19
Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int (2009) 1.17
Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study. Crit Care (2007) 1.14
The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol (2008) 1.13
Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol (2009) 1.10
Renal function and healthcare costs in patients with polycystic kidney disease. Clin J Am Soc Nephrol (2010) 1.10
Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Canc Netw (2005) 1.06
Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation (2007) 1.06
Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting. Curr Med Res Opin (2008) 1.04
Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa. Curr Med Res Opin (2006) 1.03
Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause (2011) 1.03
Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. Transfusion (2009) 0.99
Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther (2012) 0.98
Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis. Curr Med Res Opin (2008) 0.96
Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. Ann Allergy Asthma Immunol (2012) 0.95
Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol (2008) 0.95
Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient (2013) 0.94
Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs. Pediatr Blood Cancer (2013) 0.94
Using GI-specific patient outcome measures in renal transplant patients: validation of the GSRS and GIQLI. Qual Life Res (2006) 0.93
Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents. Pharmacoeconomics (2008) 0.93
Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer (2011) 0.92
Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries. Curr Med Res Opin (2009) 0.91
Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs. J Am Acad Dermatol (2006) 0.91
Anaemia and the risk of injurious falls in a community-dwelling elderly population. Drugs Aging (2008) 0.90
Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease. J Am Soc Nephrol (2006) 0.90
Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy. Epilepsy Behav (2011) 0.90
Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Appl Health Econ Health Policy (2014) 0.90
Cost burden and treatment patterns associated with management of heavy menstrual bleeding. J Womens Health (Larchmt) (2012) 0.89
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review. Support Care Cancer (2008) 0.89
Influence of early posttransplantation prednisone and calcineurin inhibitor dosages on the incidence of new-onset diabetes. Clin J Am Soc Nephrol (2007) 0.89
The impact of a food assistance program on nutritional status, disease progression, and food security among people living with HIV in Uganda. J Acquir Immune Defic Syndr (2014) 0.89
Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis. BMC Psychiatry (2013) 0.88
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review. Int J Oncol (2013) 0.87
Costs associated with cardiovascular events in patients with hypertension in US managed care settings. J Am Soc Hypertens (2010) 0.87
Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia. Leuk Lymphoma (2012) 0.86
Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy. Eur J Paediatr Neurol (2012) 0.86
All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries. J Manag Care Pharm (2012) 0.86
Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. Curr Med Res Opin (2015) 0.85
Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA. J Ophthalmic Inflamm Infect (2013) 0.85
Increased risk of graft failure in kidney transplant recipients after a diagnosis of dyspepsia or gastroesophageal reflux disease. Transplantation (2008) 0.84
The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease. Value Health (2008) 0.84
Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Curr Med Res Opin (2014) 0.84
Systematic literature review of the costs of pregnancy in the US. Pharmacoeconomics (2013) 0.84
Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation? Curr Med Res Opin (2013) 0.84
Association between consistent omalizumab treatment and asthma control. J Allergy Clin Immunol Pract (2012) 0.83
Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database. J Med Econ (2009) 0.83
Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients. J Med Econ (2010) 0.83
Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers. J Neurol Sci (2013) 0.83
Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. Expert Opin Pharmacother (2008) 0.82